Immuno-Biological Laboratories Co., Ltd. Stock

Equities

4570

JP3921300004

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
468 JPY -0.43% Intraday chart for Immuno-Biological Laboratories Co., Ltd. +7.34% -5.07%
Sales 2022 647M 4.13M Sales 2023 794M 5.06M Capitalization 3.79B 24.17M
Net income 2022 -258M -1.65M Net income 2023 -289M -1.84M EV / Sales 2022 4.28 x
Net cash position 2022 275M 1.75M Net cash position 2023 380M 2.42M EV / Sales 2023 4.3 x
P/E ratio 2022
-11.8 x
P/E ratio 2023
-13.1 x
Employees 60
Yield 2022 *
-
Yield 2023
-
Free-Float 80.46%
More Fundamentals * Assessed data
Dynamic Chart
Immuno-Biological Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
An unknown buyer agreed to acquire unknown minority stake in CURED Co., Ltd. from Immuno-Biological Laboratories Co., Ltd. CI
An undisclosed buyer acquired 26.32% stake in Cell Remover Co., Ltd. from Immuno-Biological Laboratories Co., Ltd.. CI
CURED Co., Ltd. announced that it has received ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
CURED Co., Ltd. announced that it expects to receive ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
Neo Silk Cosmetics Co., Ltd. announced that it has received ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
Neo Silk Cosmetics Co., Ltd announced that it expects to receive ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd CI
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥1.4 billion in funding from Whiz Partners Inc. CI
Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥1.39 billion in funding from Whiz Partners Inc. CI
CURED Co., Ltd. announced that it has received ¥159.6 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
CURED announced that it expects to receive ¥159.6 million in funding from Trans Genic Inc. and Immuno-Biological Laboratories Co., Ltd. CI
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it has received ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
Hideki Egawa cancelled the acquisition of 79.6 % stake in M Cosmetics Co., Ltd. from Immuno-Biological Laboratories Co., Ltd., Mitsuru Onishi and others. CI
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it expects to receive ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
More news
1 day-0.43%
1 week+7.34%
Current month-11.53%
1 month-9.13%
6 months+3.31%
Current year-5.07%
More quotes
1 week
440.00
Extreme 440
475.00
1 month
429.00
Extreme 429
541.00
Current year
408.00
Extreme 408
649.00
1 year
345.00
Extreme 345
961.00
3 years
285.00
Extreme 285
961.00
5 years
285.00
Extreme 285
1 143.00
10 years
285.00
Extreme 285
1 835.00
More quotes
Managers TitleAgeSince
President 79 82-08-31
Chief Administrative Officer 61 07-09-30
Director/Board Member 66 94-03-31
Members of the board TitleAgeSince
President 79 82-08-31
Director/Board Member 62 85-03-31
Director/Board Member 66 94-03-31
More insiders
Date Price Change Volume
24-04-26 468 -0.43% 33 900
24-04-25 470 +0.86% 16,800
24-04-24 466 +1.08% 41,000
24-04-23 461 -1.28% 44,500
24-04-22 467 +7.11% 87,900

Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT

More quotes
Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Calendar
More about the company

Annual profits - Rate of surprise